Avalo Therapeutics logo

Avalo TherapeuticsNASDAQ: AVTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 October 2015

Next earnings report:

13 May 2025

Last dividends:

N/A

Next dividends:

N/A
$114.05 M
-54%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-65%vs. 3y high
83%vs. sector
139.09
-18%vs. 3y high
96%vs. sector

Price

after hours | Wed, 20 Nov 2024 21:22:11 GMT
$10.90-$0.15(-1.36%)

Dividend

No data over the past 3 years
$249.00 K$23.04 M

Analysts recommendations

Institutional Ownership

AVTX Latest News

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
globenewswire.com12 November 2024 Sentiment: POSITIVE

WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement.

Avalo Therapeutics to Present at Upcoming Investor Conferences
globenewswire.com11 November 2024 Sentiment: POSITIVE

WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences:

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
globenewswire.com08 October 2024 Sentiment: POSITIVE

WAYNE, Pa. and ROCKVILLE, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that the first patient has been dosed in the Company's Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity.

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
globenewswire.com09 July 2024 Sentiment: POSITIVE

WAYNE, Pa. and ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS) is now active, permitting the Company to commence its Phase 2 (LOTUS) clinical trial in patients with HS. Avalo expects to enroll the first patient in its Phase 2 LOTUS Trial this year.

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
globenewswire.com24 June 2024 Sentiment: POSITIVE

WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer.

Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Zacks Investment Research02 April 2024 Sentiment: POSITIVE

Avalo (AVTX) surges on adding a new pipeline drug, which has its origins at Eli Lilly. Alongside the acquisition, it also secured funding to continue operations beyond 2027.

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?
Invezz01 April 2024 Sentiment: NEGATIVE

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of $16.60.

Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?
InvestorPlace28 March 2024 Sentiment: POSITIVE

Avalo Therapeutics (NASDAQ: AVTX ) stock is rocketing higher on Thursday after announcing a couple of positive updates for investors in the clinical-stage biotechnology company. The first big update worth noting is the company securing $185 million through a private placement.

Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
Zacks Investment Research27 March 2024 Sentiment: NEGATIVE

Avalo Therapeutics (AVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Buy Stocks for January 3rd
Zacks Investment Research03 January 2024 Sentiment: POSITIVE

GWRS, SRPT, AVTX, NTGR and PAY have been added to the Zacks Rank #1 (Strong Buy) List on January 3, 2024.

What type of business is Avalo Therapeutics?

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

What sector is Avalo Therapeutics in?

Avalo Therapeutics is in the Healthcare sector

What industry is Avalo Therapeutics in?

Avalo Therapeutics is in the Biotechnology industry

What country is Avalo Therapeutics from?

Avalo Therapeutics is headquartered in United States

When did Avalo Therapeutics go public?

Avalo Therapeutics initial public offering (IPO) was on 14 October 2015

What is Avalo Therapeutics website?

https://www.avalotx.com

Is Avalo Therapeutics in the S&P 500?

No, Avalo Therapeutics is not included in the S&P 500 index

Is Avalo Therapeutics in the NASDAQ 100?

No, Avalo Therapeutics is not included in the NASDAQ 100 index

Is Avalo Therapeutics in the Dow Jones?

No, Avalo Therapeutics is not included in the Dow Jones index

When was Avalo Therapeutics the previous earnings report?

No data

When does Avalo Therapeutics earnings report?

The next expected earnings date for Avalo Therapeutics is 13 May 2025